Introduction {#s1}
============

*Pneumocystis jirovecii* is an opportunistic fungus causing pneumonia (PCP), a severe lung disease in patients with T-lymphocyte mediated immune defect \[[@R1]\]. Historically, PCP was mainly observed among patients infected by the human immunodeficiency virus (HIV) with low CD4 count \[[@R2]\]. However, since the introduction of highly active antiretroviral therapy, the prevalence of the disease among HIV-infected patients has decreased in developed countries while the proportion of cases in non-HIV immunocompromised patients, such as haematologic cancer patients, has increased \[[@R3]\]. Mortality rates are particularly high in this latter patients' population (30--60 %) \[[@R3]\].

PCP is a life-threatening and rapidly progressive disease, which should be promptly detected \[[@R3]\]. The diagnosis of PCP is difficult because patients rarely produce sputum and invasive procedures, such as bronchoscopy, are often required to get respiratory specimens. Moreover, *P. jirovecii* cannot be isolated by routine culture methods and direct examination, albeit specific, has low sensitivity \[[@R5]\]. Molecular tools based on PCR are becoming a cornerstone for the diagnosis of PCP because of their high sensitivity for *P. jirovecii* detection \[[@R5]\]. While a negative PCR result is reliable to exclude the disease, a positive result could be difficult to interpret as it may reflect colonization instead of infection. Colonization, also referred to as asymptomatic carriage, corresponds to a situation in which the immune system is able to prevent the development of disease following recent exposure \[[@R8]\]. Because many pulmonary infections or non-infectious lung diseases may mimic PCP in non-HIV immunocompromised patients, the distinction between infection and colonization is challenging. In this study, we analysed the performance of an in-house quantitative *P. jirovecii*-specific PCR to discriminate PCP from colonization according to the fungal load in bronchoalveolar lavage fluid (BAL) in a predominantly non-HIV population.

Methods {#s2}
=======

Study design and patients {#s2-1}
-------------------------

This was a retrospective study performed at the University Hospital of Lausanne (Switzerland) from October 2007 (date of introduction of PCP quantitative PCR in clinical routine) to December 2017. All patients with a positive *P. jirovecii* PCR in a BAL were enrolled. Clinical data were collected in medical records including patients' underlying conditions, clinical and radiological presentation of pneumonia, microbiological results of BAL, therapeutic management of PCP and 12 week overall mortality. Two investigators (T.P. and A.K.) analysed the clinical data independently and without knowledge of the PCP PCR quantitative results. Irrespective of the diagnosis of PCP stated in medical records, cases were classified according to the algorithm of [Fig. 1](#F1){ref-type="fig"}. PCP diagnosis was made in the presence of all the following criteria: (i) presence of at least one host criterion as defined in [Fig. 1](#F1){ref-type="fig"}, (ii) clinical signs of respiratory infection with radiologic features consistent with PCP and (iii) presence of asci at direct examination by silver staining or introduction of antimicrobial therapy with anti-PCP activity with complete or partial improvement during the course of therapy in the absence of any alternative diagnosis. Patients were considered as 'colonized' if host criteria or clinical features of PCP were absent or if they did not receive anti-PCP therapy with a subsequent favourable outcome or a documented alternative diagnosis of respiratory infection or disease. All cases who did not fulfill the criteria of PCP or colonization were classified as 'undetermined'. Discordant classification of cases was resolved by a consensus between F.L., T.P. and A.K.

![Algorithm for classification of cases as PCP, colonization or undetermined. BAL, bronchoalveolar lavage fluid.](jmm-69-705-g001){#F1}

Diagnostic methods {#s2-2}
------------------

Direct examination of *P. jirovecii* asci in the BAL sample was performed by the rapid methenamine silver-staining method \[[@R9]\]. The real-time quantitative PCR was run on our automated molecular diagnostic platform, as previously described \[[@R10]\]. The PCP PCR targets the mitochondrial 26S rDNA. The primers and protocol used in this study have been described elsewhere \[[@R11]\]. In brief, the BAL was centrifuged 30 min at 3000 ***g*** and the pellet was resuspended in remaining 2 ml of liquid. Then, 200 µl was used for the extraction procedure. The Kit DNA Process Control (Roche Molecular Systems) was used as extraction control. Amplification and detection were performed on an Applied Biosystems Quantstudio 7 Real-Time PCR System, using a TaqMan Fast Advanced Master Mix. In order to quantify the fungal load, plasmid-positive control dilutions corresponding to 10^4^, 10^5^ and 10^6^ copies/ml were added to each run. A standard dilution curve using the cycle threshold (Ct) value of the known range of concentrations allowed the quantification of the fungal load of the original specimen in copies/ml. Plasmid positive controls are constructed according to our targeted PCR and produced by RD-Biotech, France.

PCP management {#s2-3}
--------------

Antimicrobial therapy of PCP in our institution follows international recommendations \[[@R12]\]. The recommended regimen is trimethoprim-sulfamethoxazole (TMP-SMX) at 15 mg/kg/day of the trimethoprim component divided in three daily doses (orally or intravenously) for 3 weeks. For patients with TMP-SMX allergy, treatment consist of atovaquone 750 mg twice daily for mild disease or primaquine 30 mg once daily and clindamycin 600--900 mg three times daily for moderate/severe cases. Adjunctive corticosteroids are given in case of hypoxemia (PaO~2~\<70 mmHg).

Statistical analyses {#s2-4}
--------------------

Quantitative PCR results were compared between the three groups (PCP, colonization, undetermined) using the non-parametric one-way ANOVA (Kruskal--Wallis) test with *P*-value considered as significant if ≤0.05. The performance of PCR to discriminate PCP from colonization (after exclusion of undetermined cases) among positive results was tested for different thresholds and expressed in terms of sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios.

Ethical statement {#s2-5}
-----------------

This study was approved by Swissethics (commission of the 'Canton de Vaud', project number: 2018--01220) for retrospective use of clinical data with waiver of patients' informed consent.

Results {#s3}
=======

A total of 71 patients with a positive PCP PCR result in a BAL sample were included in the analysis. As shown in [Fig. 1](#F1){ref-type="fig"} and 37 cases were classified as PCP according to the above-mentioned criteria, of which 23 (62 %) had proven infection on the basis of a positive direct examination for asci in BAL. In 22 cases, PCP was excluded because of lack of host or clinical/radiological criteria or because patients did not receive anti-PCP therapy or had an alternative diagnosis of respiratory disease. The remaining 12 cases were classified as undetermined. Characteristics of patients are described for the three groups in [Table 1](#T1){ref-type="table"}. PCP cases were mainly non-HIV patients (81 %) with haematologic cancer (51 %) or solid tumours (19 %). All patients classified as PCP or undetermined cases received anti-PCP therapy (mainly with co-trimoxazole), while 18 % of the cases classified as colonization were treated. Anti-PCP therapy was already ongoing at the time of BAL in nine (17 %) of the treated patients (median of 1 day before BAL sampling, range 1--4 days).

###### 

Characteristics of patients with a positive *P. jirovecii* PCR

                                      PCP (*N*=37)        Undetermined (*N*=12)   Colonization (*N*=22)
  ----------------------------------- ------------------- ----------------------- -----------------------
  Demographic data                                                                
    Female / Male                     22 (59) / 15 (41)   5 (42) / 7 (58)         16 (73) / 6 (27)
    Age                               59 (2--78)          64 (43--80)             61 (27--81)
  Underlying diseases                                                             
    HIV infection                     7 (19)              0 (0)                   0 (0)
    Haematologic cancer               19 (51)             4 (33)                  11 (50)
     Acute leukemia                   6 (16)              0 (0)                   3 (14)
     Lymphoproliferative disorder     6 (16)              3 (25)                  6 (27)
     Other haematologic cancer\*      7 (19)              1 (8)                   2 (9)
    Solid tumour                      7 (19)              5 (42)                  6 (27)
    Other†                            4 (11)              3 (25)                  3 (14)
  Immunosuppression                                                               
    Neutropenia (PMN\<500/mm^3^)      7 (19)              0 (0)                   4 (18)
    Lymphocyte CD4\<200/ mm^3^        18 (49)             6 (50)                  8 (36)
    Corticosteroids\>14 days          17 (46)             9 (75)                  5 (23)
    Other immunosuppressive drugs     19 (51)             7 (58)                  12 (55)
  Anti-PCP prophylaxis                4 (11)              0 (0)                   2 (9)
  Clinical/radiological features                                                  
    Hypoxemia‡                        31 (84)             9 (75)                  11 (50)
    Bilateral lung lesions            35 (95)             11 (92)                 20 (91)
    Ground-glass opacity (chest CT)   30 (81)             9 (75)                  17 (77)
  Anti-PCP therapy                                                                
    No treatment                      0 (0)               0 (0)                   18 (82)
    TMP-SMX                           37 (100)            10 (83)                 4 (18)
    Atovaquone                        0 (0)               2 (17)                  0 (0)
    Adjunctive corticosteroids        33 (89)             10 (83)                 4 (18)
  Mortality at 12 weeks               10 (27)             4 (33)                  7 (32)

Values are absolute numbers (percentage) for proportions and median (range) for continuous variables.

\*Other haematologic cancer: multiple myeloma, myelodysplastic syndrome or myeloproliferative disorder

†Auto-immune disorders or solid-organ transplantation.

‡Room air PaO~2~ \<70 mmHg or O~2~ saturation \<92 %.

PCP, *P. jirovecii* pneumonia; HIV, human immunodeficiency virus; PMN, polymorphonuclear neutrophils; TMP-SMX, trimethoprim-sulfamethoxazole.

The quantitative results of PCP PCR were significantly higher among PCP cases compared to both undetermined and colonized cases ([Fig. 2](#F2){ref-type="fig"}). The performance of the quantitative PCR to discriminate PCP from colonization for different thresholds is shown in [Table 2](#T2){ref-type="table"}. The optimal result was obtained for a cut-off of 5×10^3^ copies/ml with a sensitivity, specificity, positive and negative predictive value of 97, 82, 90 and 95 %, respectively. A 100 % sensitivity and negative predictive value were obtained for the cut-off of 10^3^ copies/ml, while a cut-off of 5×10^5^ copies/ml was associated with 100 % specificity and positive predictive value.

![Comparison of *P. jirovecii* quantitative PCR results between PCP, colonization and undetermined cases. Analysis performed by non-parametric one-way ANOVA (Kruskal--Wallis) test with *P*-value considered as significant if ≤0.05. \*\*\*\* *P* value \<0.0001.](jmm-69-705-g002){#F2}

###### 

Diagnostic performance of *P. jirovecii* PCR for the discrimination between PCP and colonization

  Cut-off   Sensitivity   Specificity   PPV    NPV    LR +    LR -   DOR
  --------- ------------- ------------- ------ ------ ------- ------ -------
  10^2^     1             0.05          0.64   1      1.05    0      NC
  5×10^2^   1             0.23          0.69   1      1.29    0      NC
  10^3^     1             0.36          0.73   1      1.57    0      NC
  5×10^3^   0.97          0.82          0.90   0.95   5.35    0.03   162
  10^4^     0.95          0.82          0.90   0.90   5.20    0.07   78.75
  5×10^4^   0.81          0.91          0.94   0.74   8.92    0.21   42.86
  10^5^     0.76          0.95          0.97   0.70   16.65   0.25   65.33
  5×10^5^   0.62          1             1      0.61   NC      0.38   NC
  10^6^     0.51          1             1      0.55   NC      0.49   NC
  5×10^6^   0.30          1             1      0.46   NC      0.70   NC
  10^7^     0.30          1             1      0.46   NC      0.70   NC

DOR, diagnostic odds ratio; LR+, positive likelihood ratio; LR-, negative likelihood ratio; NC, not calculated; NPV, negative predictive value; PPV, positive predictive value.

Discussion {#s4}
==========

PCP is increasingly observed among non-HIV patients with different types and intensity of immunosuppression. Atypical clinical presentation and concomitant respiratory infections are frequent in this population making PCP diagnosis particularly challenging. Our analysis suggests an excellent ability of our quantitative PCR to discriminate PCP from colonization in a predominantly non-HIV population with a suggested cut-off of 5×10^3^ copies/ml.

Some studies have previously assessed the performance of quantitative PCR cut-off values to distinguish PCP from colonization \[[@R13]\]. These studies (compared in [Table 3](#T3){ref-type="table"}) exhibit important heterogeneity regarding the type of population (proportion of HIV and non-HIV patients), the type of sample (BAL only or including induced sputum samples), the PCR target (mitochondrial rRNA, dihydropteroate synthase gene, major surface glycoprotein), the quantification method of fungal load (Ct cycles or copies per ml), the definition of PCP cases (i.e. clinical criteria to distinguish probable cases from colonization), and the expression of results. Similarly to our analysis, most studies demonstrate significant differences of mean fungal loads between the categories of proven PCP, versus probable/possible cases and colonization. However, the assessment of an acceptable fungal load cut-off for distinguishing PCP from colonization gives various results. While most studies suggest a 'grey zone' between cut-offs providing near 100 % positive/negative predictive values for PCP diagnosis, some of them found a large and overlapping distribution precluding the assessment of a reliable cut-off \[[@R15]\]. Compared to previous analyses, our study has the highest number and proportion of haematologic cancer patients. Diagnosis of PCP is notoriously difficult in this population exposed to various types of lung injury including infectious causes and secondary effects of anti-cancer therapy \[[@R19]\].

###### 

Comparative performance of quantitative *P. jirovecii* PCR in various studies

+----------------------------------+---------------------------------------+-------------------------+------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------+
| Study                            | PCR target                            | No. of PCP cases\*      | PCP classification†                                              | Results                                                                                                    |
|                                  |                                       |                         |                                                                  |                                                                                                            |
| first author, year (reference)   |                                       | HIV / HM / others \[%\] |                                                                  |                                                                                                            |
+==================================+=======================================+=========================+==================================================================+============================================================================================================+
| Alanio, 2011 \[[@R13]\]          | Mitochondrial large-subunit rRNA gene | 16                      | High vs low probability                                          | \<120 TFEq/ml: 100 % NPV                                                                                   |
|                                  |                                       |                         |                                                                  |                                                                                                            |
|                                  |                                       | 56/19/25                |                                                                  | \>1900 TFEq/ml: 100 % PPV                                                                                  |
+----------------------------------+---------------------------------------+-------------------------+------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------+
| Botterel, 2012 \[[@R14]\]        | Mitochondrial large-subunit rRNA gene | 17                      | Proven vs IFA-negative                                           | ≤2.6 log~10~ copies/µl: 100 % NPV                                                                          |
|                                  |                                       |                         |                                                                  |                                                                                                            |
|                                  |                                       | 47/35/18                |                                                                  | ≥4 log~10~ copies/µl: 100 % PPV                                                                            |
+----------------------------------+---------------------------------------+-------------------------+------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------+
| Matsumura, 2016 \[[@R17]\]       | Dihydropteroate synthase gene         | 53                      | \(a\) Proven vs colonization (b) proven/probable vs colonization | \(a\) 1300 copies/ml: 100 % NPV, 79 % PPV (b) 340 copies/ml: 44 % NPV, 91 % PPV                            |
|                                  |                                       |                         |                                                                  |                                                                                                            |
|                                  |                                       | 9/17/74                 |                                                                  |                                                                                                            |
+----------------------------------+---------------------------------------+-------------------------+------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------+
| Robert-Gangneux, 2014 \[[@R18]\] | Mitochondrial large-subunit rRNA gene | 35                      | Proven/probable vs possible vs colonization                      | Significant differences of fungal load (Ct value between groups). Large distribution, no cut-off proposed. |
|                                  |                                       |                         |                                                                  |                                                                                                            |
|                                  |                                       | 12/37/51                |                                                                  |                                                                                                            |
+----------------------------------+---------------------------------------+-------------------------+------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------+
| Maillet, 2014 \[[@R16]\]         | Major surface glycoprotein            | 11                      | Proven/probable vs possible/colonization                         | ≤3160 copies/ml: 100 % NPV                                                                                 |
|                                  |                                       |                         |                                                                  |                                                                                                            |
|                                  |                                       | 18/73/9                 |                                                                  | ≥31 600 copies/ml: 100 % PPV                                                                               |
+----------------------------------+---------------------------------------+-------------------------+------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------+
| Fauchier. 2016 \[[@R15]\]        | Mitochondrial large-subunit rRNA gene | 73                      | Proven/probable vs colonization (no possible category)           | Ct 32 : 72 % sen, 75 % spe                                                                                 |
|                                  |                                       |                         |                                                                  |                                                                                                            |
|                                  |                                       | 41/26/33                |                                                                  | Ct \>35: exclusion PCP (80%sen/63%spe)                                                                     |
+----------------------------------+---------------------------------------+-------------------------+------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------+
| Kritikos, 2020                   | Mitochondrial 26S rDNA                | 37                      | Proven/probable vs colonized                                     | ≤10^3^ copies/ml: 100 % NPV                                                                                |
|                                  |                                       |                         |                                                                  |                                                                                                            |
| (present study)                  |                                       | 19/51/30                | (possible excluded)                                              | 5×10^3^ copies/ml: 95 % NPV, 90 % PPV                                                                      |
|                                  |                                       |                         |                                                                  |                                                                                                            |
|                                  |                                       |                         |                                                                  | ≥5×10^5^ copies/ml: 100 % PPV                                                                              |
+----------------------------------+---------------------------------------+-------------------------+------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------+

\*Patients with PCP classified as proven or probable.

†Nomenclature for PCP classification: proven: IFA positive, probable: IFA negative / PCR positive, with defined clinical criteria for PCP diagnosis, possible: IFA negative / PCR positive, without fulfilling all clinical criteria for PCP diagnosis. Colonization: IFA negative / PCR positive, and no PCP diagnosis retained on the basis of clinical assessment.

HIV, human immunodeficiency virus; HM, haematologic malignancies; IFA, immunofluorescence assay; NPV, negative predictive value; PCP, *P. jirovecii* pneumonia; Sen, sensitivity; Spe, specificity; TFEq, trophic form equivalents.

The absence of a reliable gold standard to define PCP infection is an important limitation. In this study, we used stringent criteria to define PCP with a majority of patients (62 %) with proven infection on the basis of a positive direct examination and the remaining cases having responded to anti-PCP therapy in the absence of alternative diagnosis. Nonetheless, a small proportion of cases were classified as undetermined and were excluded from the analysis. The median fungal burden among these patients was close to the cut-off, suggesting a grey zone in the interpretation. However, our results suggest a reliable and relatively narrow cut-off margin with values \<10^3^ and \>5×10^3^ copies/ml providing 100 and 90% negative and positive predictive values, respectively, which seems appropriate to trigger therapeutic decisions. Targeted treatment of PCP cases based on reliable PCR cut-offs may avoid unnecessary use of antimicrobial agents and their associated risks of toxicity or resistance.

Use of the 1,3-beta-[d]{.smallcaps}-glucan test in serum could be helpful for the assessment of PCP probability. Unfortunately, BDG results were not available for most cases of the present study, as the test was introduced in our institution only at the end of the study period. Another limitation consisted of the absence of negative controls. However, the excellent negative predictive value of PCP PCR (≥99 %) has already been established \[[@R5]\]. Accordingly, we did not observe any confirmed case of PCP with a negative PCR result during the study period. The actual challenge for PCP diagnosis relies on the discrimination between PCP and colonization among patients with a positive PCR result, which was the specific question addressed in the present study. Other roles of PCP PCR, for instance as a screening tool in the setting of nosocomial PCP outbreaks, could also be investigated in the future \[[@R20]\].

In conclusion, quantitative PCP PCR results in BAL were reliable to distinguish infection from colonization in this predominantly non-HIV population and may be used to guide therapeutic decisions. Thresholds should be assessed for each individual in-house PCR method, as different values may be observed according to the molecular method and/or patients' population. Development of standardized procedures and commercial kits for quantitative PCP PCR is warranted. Such efforts of standardization with comparison of PCP PCR performance across centres and between different assays are ongoing \[[@R22]\].
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